309 related articles for article (PubMed ID: 19462824)
41. [Antiandrogen suppression syndrome in patients with hormone-resistant cancer of the prostate].
Morote Robles J; Lorente Garín JA; Encabo G
Actas Urol Esp; 1998 Sep; 22(8):661-5. PubMed ID: 9835085
[TBL] [Abstract][Full Text] [Related]
42. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
43. The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
Ohlson N; Bergh A; Nygren K; Stattin P; Wikström P
Eur Urol; 2006 Apr; 49(4):675-83. PubMed ID: 16387414
[TBL] [Abstract][Full Text] [Related]
44. [Monotherapy versus combined androgen blockade for advanced/metastatic prostate cancer].
Iida K
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2553-7. PubMed ID: 22189220
[TBL] [Abstract][Full Text] [Related]
45. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
Shimada M; Uchida H; Kasahara T; Fuji K; Ogawa Y; Yoshida H; Hamajima T; Matsuda N; Ikeuchi T; Kai Y; Hiramori M; Hoshino M; Inoue K; Higaki Y
Hinyokika Kiyo; 1998 Jul; 44(7):525-32. PubMed ID: 9752613
[TBL] [Abstract][Full Text] [Related]
46. [Antiandrogen withdrawal syndrome].
Akimoto S
Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
[TBL] [Abstract][Full Text] [Related]
47. Antiandrogens in the treatment of prostate cancer.
Wirth MP; Hakenberg OW; Froehner M
Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995
[TBL] [Abstract][Full Text] [Related]
48. [Papillary adenocarcinoma of the prostate with good response to antiandrogen therapy and delayed radiotherapy: a case report].
Ishizu K; Konishi M; Joko K; Takihara H; Sakatoku J; Tanaka K
Hinyokika Kiyo; 1992 Mar; 38(3):343-6. PubMed ID: 1381864
[TBL] [Abstract][Full Text] [Related]
49. Preoperative administration of chlormadinone acetate reduces blood loss associated with transurethral resection of the prostate: a prospective randomized study.
Ukimura O; Kawauchi A; Kanazawa M; Miyashita H; Yoneda K; Kojima M; Nakanouchi T; Miki T;
BJU Int; 2005 Jul; 96(1):98-102. PubMed ID: 15963129
[TBL] [Abstract][Full Text] [Related]
50. Oncological outcomes of hormonal therapy with a gonadotropin-releasing hormone agonist combined with a steroidal or non-steroidal antiandrogen in patients with prostate cancer.
Igawa T; Tsurusaki T; Nomata K; Hayashi M; Furukawa M; Sakai H
Anticancer Res; 2014 Apr; 34(4):1983-8. PubMed ID: 24692735
[TBL] [Abstract][Full Text] [Related]
51. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
[TBL] [Abstract][Full Text] [Related]
52. [Clinical evaluation of CMA in the treatment of prostatic cancer].
Fukuoka H; Goto A; Murai T; Satomi Y; Moriyama M; Senga Y; Shirai K; Nakao H
Hinyokika Kiyo; 1986 Dec; 32(12):1821-30. PubMed ID: 2435131
[TBL] [Abstract][Full Text] [Related]
53. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer.
Denham JW; Kumar M; Gleeson PS; Lamb DS; Joseph D; Atkinson C; Matthews J; Tai KH; Spry NA; Christie D; Turner S; Greer PB; D'Este C; Steigler A
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):404-11. PubMed ID: 19176272
[TBL] [Abstract][Full Text] [Related]
54. [Application of antiandrogens on prostatic diseases].
Takahashi S; Hasegawa F; Isurugi K
Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
[TBL] [Abstract][Full Text] [Related]
55. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
Kanimoto Y; Okada K
Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
[TBL] [Abstract][Full Text] [Related]
56. A prospective randomized multicenter study of chlormadinone acetate versus flutamide in total androgen blockade for prostate cancer.
Ozono S; Okajima E; Yamaguchi A; Yoshikawa M; Iwai A; Moriya A; Yoshida K; Samma S; Maruyama Y; Hirao Y
Jpn J Clin Oncol; 2000 Sep; 30(9):389-96. PubMed ID: 11095136
[TBL] [Abstract][Full Text] [Related]
57. [Maximal androgen blockade and maximal androgen blockade combined with 125I brachytherapy for prostatic cancer].
Su Y; Yao MY; Yuan Z; Yang JJ; Liu J; Hu XN
Zhonghua Nan Ke Xue; 2003 Sep; 9(6):434-5. PubMed ID: 14574808
[TBL] [Abstract][Full Text] [Related]
58. Local injection of a sustained-release antiandrogen formulation into a target prostatic site: an experimental study.
Goya N; Gotanda K; Sasaki T; Okada M; Tomizawa Y; Toma H
BJU Int; 2007 Jan; 99(1):202-6. PubMed ID: 17092292
[TBL] [Abstract][Full Text] [Related]
59. Molecular basis for the antiandrogen withdrawal syndrome.
Miyamoto H; Rahman MM; Chang C
J Cell Biochem; 2004 Jan; 91(1):3-12. PubMed ID: 14689576
[TBL] [Abstract][Full Text] [Related]
60. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
